nusinersen (Spinraza) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drugs@FDA PubChem

Active Ingredient History

NOW
  • Now
Nusinersen, marketed as Spinraza, is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. In December 2016, it became the first approved drug used in treating this disorder.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$18501.3740 - $25499.9500

Australia

$85283.0000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

isis 396443 | isis-396443 | isis-smnrx | nusinersen | nusinersen sodium | spinraza

Organizations (6)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Muscular Atrophy, Spinal

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Muscular Atrophy, Spinal (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue